At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
Princess FILLER Lidocainedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open Label, Multicenter, Post Market Study Evaluating Princess® FILLER Lidocaine for the Correction of Nasolabial Folds
In Brief
A clinical study evaluating Princess FILLER Lidocaine for Correction of Nasolabial Folds. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
In this study, eligible subjects with moderate to severe nasolabial folds will be treated with Princess® FILLER Lidocaine and will return for follow-up assessments 2, 4, 24 and 36 weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate by the investigator
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorrection of Nasolabial Folds
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedAug 2018
Primary CompletionNov 2018
TodayJul 2026
First PostedAug 2, 2018
Enrollment StartSep 20, 2017
Primary CompletionNov 19, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.9 years ago
Interventions
Princess FILLER Lidocainedevice
Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.